

Held the 26th DAAC (Dong-A Anti-Corruption Committee) meeting
Held the 4th, 5th DCPC (Dong-A ST Compliance Committee) meeting
Submitted public disclosure materials for the EconomicBenefit Expenditure Report

Held the 3rd DCPC (Dong-A ST Compliance Committee)
meeting of 2025
Conducted ISO 37001 internal auditor competency training
Completed ISO 37001 surveillance audit
Held the 25th DAAC (Dong-A Anti-Corruption Committee) meeting
Held the 2nd DCPC (Dong-A ST Compliance Committee)
meeting of 2025
Identified corruption risks and set anti-bribery objectives
for each department under ISO 37001

Collected Compliance Pledge forms from all employees
(1,526 participants)
Conducted first-half CP training for the ETC and DH
Business Division (563 participants, 562 completed)
Held the 1st DCPC (Dong-A ST Compliance Committee)
meeting of 2025
Held the 24th DAAC (Dong-A Anti-Corruption Committee) meeting
Reported ISO 37001 management review results to the
Board of Directors
Held the 2025 Compliance Program Enhancement Declaration Ceremony
Conducted ISO 37001 management review by top management

Received an ‘A’ grade in the CP rating evaluation from
the Korea Fair Trade Commission
Conducted ISO 37001 second-half monitoring
Conducted CP training for new MRs in the ETC Business Division
Held the 6th DCPC (Dong-A Compliance Committee)
meeting of 2024
Conducted regular online CP training for all employees
(1,615 participants, 99.9% completion)
Conducted CP awareness survey
Conducted second-half CP training for the ETC Business Division, Marketing Division, and Medical Device Division
(576 participants, 100% completion)
Conducted ISO 37001 internal audit (37 teams across all business divisions)
Held the 5th DCPC (Dong-A ST Compliance Committee)
meeting of 2024

Held the 23rd DAAC (Dong-A Anti-Corruption Committee) meeting
Held the 4th DCPC (Dong-A ST Compliance Committee)
meeting of 2024
Submitted public disclosure materials for the Economic
Benefit Expenditure Report
Conducted CP training for employees who violated
compliance regulations during the first half of the year
Conducted first-half ISO 37001 monitoring

Held the 3rd DCPC (Dong-A ST Compliance Committee)
meeting of 2024
Held the 22nd DAAC (Dong-A Anti-Corruption Committee) meeting
Completed ISO 37001 certification renewal
Held the 21st DAAC (Dong-A Anti-Corruption Committee) meeting
Applied for the 2024 CP Rating Evaluation (Korea Fair Trade Mediation Agency)
Held the 2nd DCPC (Dong-A ST Compliance Committee)
meeting of 2024
Conducted CP training for executives with an invited external lecturer

Collected Compliance Pledge forms from all employees
(1,580 participants)
Conducted first-half CP training for the ETC Business Division, Marketing Division, and Medical Device Division
(580 participants, 100% completion)
Identified corruption risks and set anti-bribery objectives
for each department under ISO 37001
Reported ISO 37001 management review results to the
Board of Directors
Held the 1st DCPC (Dong-A ST Compliance Committee)
meeting of 2024
Conducted ISO 37001 management review by top management
Held the 2024 Compliance Program Declaration Ceremony

Conducted ISO 37001 second-half monitoring
Conducted ISO 37001 internal audit covering all business divisions (41 teams audited)
Conducted regular online ISO 37001/ESG training for all employees (1,625 participants, 100% completion)
Conducted employee awareness survey on sustainable management (600 respondents out of 1,625 employees)
Hosted the 1st Dong-A ST Supply Chain Partners Day
(19 Tier-1 partner companies participated)
Conducted second-half CP training for the ETC Business
Division and the Medical Device Division
(120 participants, 100% completion)
Conducted second-half CP training for the ETC Business Division

Conducted second-half CP training for the ETC Business Division (400 participants, 100% completion)
Conducted online ISO 37001 training for managers
(223 participants, 100% completion)
Conducted CP training for Dong-A Chammed (Ethics Code and Medical Device Fair Competition Code of Conduct)
Conducted first-half ISO 37001 monitoring
Held the 20th DAAC (Dong-A Anti-Corruption Committee) meeting

Respond to the Economic Benefit Expenditure Report survey (submitted 2022 expenditure report data)
Conducted CP monitoring on ETC Distribution Policy
Conducted CP monitoring on the Wholesale Sales Policy of the Distribution Management Department
Conducted CP training for Dong-A Chammed (affiliate company)
Conducted CP monitoring for the Medical Device Division
Conducted CP monitoring for a affiliated companies
Conducted first-half CP training for the ETC Business
Division and the Medical Device Division
(520 participants, 100% completion)

Collected Compliance Pledge forms from all employees
(1,621 participants, 100% completion)
Reported ISO 37001 management review results to the
Board of Directors
Identified corruption risks and set anti-bribery objectives
for each department under ISO 37001
Conducted ISO 37001 management review by top management
Conducted CP training for new MRs in the ETC Business Division

Conducted ISO 37001 second-half monitoring
Provided CP training for the Marketing Division (51 participants)
Conducted online CP/ESG training for all employees
(1,593 participants, 100% completion)
Conducted second-half CP training for the ETC Business Division
(317 participants)

Conducted CP refresher training for new MRs in the ETC Sales Division (20 participants)
Conducted CP training for newly hired employee in the ETC Division (11 participants)
Conducted CP training for new PMs in the Marketing Division
(3 participants)

Conducted first-half CP training for the Medical Device and Diagnostic Divisions (54 participants)
Conducted first-half CP training for the ETC Business
Division (480 sales representatives)

Conducted CP training for new PMs in the Marketing Division
(5 participants)
Conducted Business Partner CP training for the medical
Device Division (50 participants)


Dong-A ST conducts an annual risk assessment for relevant department to ensure that rebate practices, which could undermine the company’s business foundation, do not occur.
We also conduct continuous risk management and assess its effectiveness based on the results of the risk assessment




The company and its employees will strictly comply with all domestic and international
anti-corruption laws and internal regulations, prohibiting all forms of corruption.
We will establish and continuously improve systems related to anti-corruption to meet our objectives.
Employees are encouraged to promptly report any corruption, and the company will ensure
that whistleblowers are fully protected from retaliation.
The anti-bribery officer will be granted the authority and independence needed to oversee anti-bribery efforts.
A zero-tolerance policy will be enforced for employee corruption,
with strict penalties applied according to company regulations.
We will ensure that our anti-bribery policy is effectively communicated to all relevant business stakeholders.
